» Articles » PMID: 18573897

Characterization of Human Cellular Immune Responses to Novel Mycobacterium Tuberculosis Antigens Encoded by Genomic Regions Absent in Mycobacterium Bovis BCG

Overview
Journal Infect Immun
Date 2008 Jun 25
PMID 18573897
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Comparative genomics has identified several regions of differences (RDs) between the infectious Mycobacterium tuberculosis and the vaccine strains of Mycobacterium bovis BCG. We aimed to evaluate the cellular immune responses induced by antigens encoded by genes predicted in 11 RDs. Synthetic peptides covering the sequences of RD1, RD4 to RD7, RD9 to RD13, and RD15 were tested for antigen-induced proliferation and secretion of Th1 cytokine, gamma interferon (IFN-gamma), by peripheral blood mononuclear cells (PBMC) obtained from culture-proven pulmonary tuberculosis (TB) patients and M. bovis BCG-vaccinated healthy subjects. Among the peptide pools, RD1 induced the best responses in both donor groups and in both assays. In addition, testing of TB patients' PBMC for secretion of proinflammatory cytokines (tumor necrosis factor alpha [TNF-alpha], interleukin 6 [IL-6], IL-8, and IL-1beta), Th1 cytokines (IFN-gamma, IL-2, and TNF-beta), and Th2 cytokines (IL-4, IL-5, and IL-10) showed differential effects of RD peptides in the secretion of IFN-gamma and IL-10, with high IFN-gamma/IL-10 ratios (32 to 5.0) in response to RD1, RD5, RD7, RD9, and RD10 and low IFN-gamma/IL-10 ratios (<1.0) in response to RD12, RD13, and RD15. Peptide-mixing experiments with PBMC from healthy subjects showed that secretion of large quantities of IL-10 in response to RD12 and RD13 correlated with inhibition of Th1 responses induced by RD1 peptides. In conclusion, our results suggest that M. tuberculosis RDs can be divided into two major groups--one group that activates PBMC to preferentially secrete IFN-gamma and another group that activates preferential secretion of IL-10--and that these two groups of RDs may have roles in protection against and pathogenesis of TB, respectively.

Citing Articles

PPE59 antibodies in tuberculous patients and potential use for diagnosis when assayed with other rapid biomarkers.

Mulinari A, Sardella I, da Silva V, Matteelli A, Carvalho A, Saad M Mem Inst Oswaldo Cruz. 2024; 119:e230183.

PMID: 39292107 PMC: 11404981. DOI: 10.1590/0074-02760230183.


Expression and purification of Rv2654 recombinant protein from and its characteristics of immune response.

Chen F, Zhu Q, Yu Y, Wan K, Luo Q, Yu P Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(9):925-931.

PMID: 34707001 PMC: 10930181. DOI: 10.11817/j.issn.1672-7347.2021.210318.


Immunological Characterization of Proteins Expressed by Genes Located in -Specific Genomic Regions Encoding the ESAT6-like Proteins.

Mustafa A Vaccines (Basel). 2021; 9(1).

PMID: 33430286 PMC: 7825740. DOI: 10.3390/vaccines9010027.


Vaccine Potential of Mycobacterial Antigens against Asthma.

Mustafa A Med Princ Pract. 2020; 29(5):404-411.

PMID: 32422630 PMC: 7511680. DOI: 10.1159/000508719.


The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins.

Safar H, Mustafa A, Amoudy H, El-Hashim A PLoS One. 2020; 15(2):e0228381.

PMID: 32027660 PMC: 7004338. DOI: 10.1371/journal.pone.0228381.


References
1.
Mustafa A, Lundin K, Oftung F . Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae. Infect Immun. 1993; 61(12):5294-301. PMC: 281314. DOI: 10.1128/iai.61.12.5294-5301.1993. View

2.
Marchant A, Amedei A, Azzurri A, Vekemans J, Benagiano M, Tamburini C . Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am J Respir Cell Mol Biol. 2001; 24(2):187-94. DOI: 10.1165/ajrcmb.24.2.4274. View

3.
Mustafa A . Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Curr Pharm Biotechnol. 2001; 2(2):157-73. DOI: 10.2174/1389201013378707. View

4.
Behr M, Wilson M, Gill W, Salamon H, Schoolnik G, Rane S . Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999; 284(5419):1520-3. DOI: 10.1126/science.284.5419.1520. View

5.
Brosch R, Gordon S, Pym A, Eiglmeier K, Garnier T, Cole S . Comparative genomics of the mycobacteria. Int J Med Microbiol. 2000; 290(2):143-52. DOI: 10.1016/S1438-4221(00)80083-1. View